Vimian Group walked into today’s Q3 2026 report with the stock closing at SEK40.05 and a strong run over the past three months. The headline was clear: revenue reached €121.4m while net income landed at €8.9m, and the trailing 12 month net margin sat at 8.3%. Shares have already priced in high expectations, helped by a P/E of 48.8x, so even solid animal health earnings can feel underwhelming. The real question for investors is whether today’s reaction reflects fundamentals or just nerves about paying up for growth.
Love Vimian Group’s revenue scale but hesitant about paying almost 49x earnings for it? Compare that setup with our 191 high quality undervalued stocks to see stocks that pair quality fundamentals with less demanding valuations.
Q3 2026 Earnings Summary
- Revenue (Q3 2026 vs Q3 2025): €121.4m vs. €104.3m (up about 16%)
- Net Income (Excl. Extra Items, Q3 2026 vs Q3 2025): €8.9m vs. €6.5m (up about 37%)
- Basic EPS (Q3 2026 vs Q3 2025): €0.0167 vs. €0.0123 (up about 35%)
- Net Profit Margin (Trailing 12 Months vs Prior Year): 8.3% vs. 7.5% (margin higher year on year)
Skip the 10,000 word call recap. Ask Charlie what Vimian’s 2030 roadmap could change for investors.
Vimian Bull Case Hinges On Execution Milestones
The bullish story around Vimian Group rests on recent investments translating into self sustaining growth rather than just one off M&A boosts.
"The main factor that has to go right is that Vimian Group converts recent investments in U.S. orthopedics, new Veterinary Services markets such as Japan, Portugal and Ireland, and its active M&A pipeline into sustained organic growth with margins around current levels or better."
Q3 gives some evidence this is happening. Organic growth of 11% shows the underlying engine is working. MedTech delivered double digit expansion with North American orthopedics back to low single digit progress, helped by the expanded field salesforce. Veterinary Services reached 12,400 member clinics with roughly 10% organic growth and margins around 30%, broadly consistent with the margin ambition in the thesis.
The price and this Narrative do not agree. → Uncover what this Narrative says Vimian Group is actually worth.
Vimian Bear Case: Margin Strain And M&A Dependence Tested
The harsher view on Vimian Group says growth leans too heavily on deals and new projects that may not pull their weight in profit terms.
"Continued reliance on an active M&A pipeline across Diagnostics, Veterinary Services and MedTech adds future integration, legal and financing needs on top of rising net debt, and any slowdown in acquired revenue contribution or weaker cash conversion could make it harder for Vimian Group to support earnings growth while maintaining current leverage and margin levels."
Q3 cash conversion of 71% and leverage at 2.0x show no breakage yet, but the warning is not disproved. Central costs rose, Diagnostics margins stayed low, and management still talks about further acquisitions and near term margin stability rather than clear uplift. The dependency on integration working smoothly remains.
Hunt For Mispriced Earnings Power
Vimian Group reminded investors how difficult it can be to align expectations, execution and valuation in a single quarter. The real opportunity is identifying stocks that could be undervalued before the market reassesses them.
- Company 1 - 29% below our estimate - deepens a payments led ecosystem that nudges customers toward digital lending and fee based services.
- Company 2 - 23% below our estimate - ramps healthcare elastomer components as new capacity, capsule integration and footprint changes enhance product mix.
- Company 3 - 44% below our estimate - converts port automation and electrification projects into longer lifecycle service contracts and recurring maintenance revenue.
Those are three of them. See every one of the 191 undervalued companies on it →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com